Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 6 | 3 |
| List of Figures | 9 | 2 |
| Therapeutic Proteins Market: Introduction | 11 | 1 |
| GBI Research Report Guidance | 11 | 1 |
| Therapeutic Proteins Market: Market Overview | 12 | 2 |
| Introduction | 12 | 1 |
| Drivers and Barriers | 12 | 1 |
| Drivers for the Therapeutic Proteins Market | 13 | 1 |
| Barriers for the Therapeutic Proteins Market | 13 | 1 |
| Therapeutic Proteins Market: Market Characterization | 14 | 1 |
| Market Size | 14 | 1 |
| Therapeutic Proteins Market: Geographical Landscape | 15 | 3 |
| Revenue Analysis by Geography | 15 | 1 |
| The US | 15 | 1 |
| Market Size | 15 | 1 |
| Europe | 16 | 1 |
| Market Size | 16 | 1 |
| ROW (Rest of the World) | 17 | 1 |
| Market Size | 17 | 1 |
| Therapeutic Proteins Market: Therapeutic Landscape | 18 | 42 |
| Introduction | 18 | 1 |
| Erythropoietins Market | 18 | 1 |
| Introduction | 18 | 1 |
| Market Size | 19 | 1 |
| The US Market | 20 | 1 |
| Europe | 21 | 1 |
| ROW | 22 | 1 |
| Annual Cost of Treatment for Major Therapies | 23 | 1 |
| Blood Factors Market | 24 | 1 |
| Introduction | 24 | 1 |
| Market Size | 25 | 1 |
| The US | 26 | 1 |
| Europe | 27 | 1 |
| ROW | 28 | 1 |
| Annual Cost of Treatment for Major Therapies | 29 | 1 |
| Interferons Market | 30 | 1 |
| Introduction | 30 | 1 |
| Market Size | 31 | 1 |
| The US | 32 | 1 |
| Europe | 33 | 1 |
| ROW | 34 | 1 |
| Annual Cost of Treatment for Major Therapies | 35 | 1 |
| Monoclonal Antibodies Market | 36 | 1 |
| Introduction | 36 | 1 |
| Market Size | 37 | 1 |
| The US | 38 | 1 |
| Europe | 39 | 1 |
| ROW | 40 | 1 |
| Annual Cost of Treatment for Major Therapies | 41 | 1 |
| Growth Hormones Market | 42 | 1 |
| Introduction | 42 | 1 |
| Market Size | 43 | 1 |
| The US | 44 | 1 |
| Europe | 45 | 1 |
| ROW | 46 | 1 |
| Annual Cost of Treatment for Major Therapies | 47 | 1 |
| Insulin Market | 48 | 1 |
| Introduction | 48 | 1 |
| Market Size | 49 | 1 |
| The US | 50 | 1 |
| Europe | 51 | 1 |
| ROW | 52 | 1 |
| Annual Cost of Treatment for Major Therapies | 53 | 1 |
| Colony Stimulating Factors Market | 54 | 1 |
| Introduction | 54 | 1 |
| Market Size | 55 | 1 |
| The US | 56 | 1 |
| Europe | 57 | 1 |
| ROW | 58 | 1 |
| Annual Cost of Treatment for Major Therapies | 59 | 1 |
| Therapeutic Proteins Market: Pipeline Analysis | 60 | 9 |
| Introduction | 60 | 1 |
| Profiles of Promising Proteins in the Therapeutic Proteins Market | 60 | 1 |
| rhGAD65 (Diamyd) | 60 | 1 |
| Overview | 60 | 1 |
| Efficacy | 60 | 1 |
| Safety | 60 | 1 |
| Clinical Study Details | 60 | 1 |
| DiaPep277 | 60 | 1 |
| Overview | 60 | 1 |
| Efficacy | 61 | 1 |
| Safety | 61 | 1 |
| Clinical Study Details | 61 | 1 |
| Otelixizumab | 61 | 1 |
| Overview | 61 | 1 |
| Efficacy | 61 | 1 |
| Safety | 61 | 1 |
| Clinical Trial Data | 61 | 1 |
| Oral-Lyn | 62 | 1 |
| Overview | 62 | 1 |
| Efficacy | 62 | 1 |
| Safety | 62 | 1 |
| Clinical Trial Data | 62 | 1 |
| NecLip-pdFVIII | 62 | 1 |
| Overview | 62 | 1 |
| Efficacy | 63 | 1 |
| Safety | 63 | 1 |
| Clinical Trial Study Details | 63 | 1 |
| OBI-1 | 63 | 1 |
| Overview | 63 | 1 |
| Efficacy | 63 | 1 |
| Safety | 63 | 1 |
| Clinical Trial Data | 64 | 1 |
| NN7008 | 64 | 1 |
| Overview | 64 | 1 |
| Efficacy | 64 | 1 |
| Safety | 64 | 1 |
| Clinical Trial Data | 64 | 1 |
| Long Acting rFactor VIII | 65 | 1 |
| Overview | 65 | 1 |
| Efficacy | 65 | 1 |
| Safety | 65 | 1 |
| Clinical Trial Data | 65 | 1 |
| Human-cl rhFVIII | 66 | 1 |
| Overview | 66 | 1 |
| Efficacy | 66 | 1 |
| Safety | 66 | 1 |
| Clinical Trial Data | 66 | 1 |
| Abthrax (raxibacumab) | 67 | 1 |
| Overview | 67 | 1 |
| Efficacy | 67 | 1 |
| Safety | 67 | 1 |
| Clinical Trial Data | 67 | 1 |
| Simponi (golimumab) | 68 | 1 |
| Overview | 68 | 1 |
| Efficacy | 68 | 1 |
| Safety | 68 | 1 |
| Clinical Trial Data | 68 | 1 |
| Therapeutic Proteins Market: Competitive Landscape | 69 | 52 |
| Evolving Competitive Landscape | 69 | 1 |
| Market Share Analysis | 69 | 1 |
| Major Companies | 69 | 1 |
| Competitive Profiling | 70 | 1 |
| Pfizer | 70 | 1 |
| Company Overview | 70 | 9 |
| Johnson &Johnson | 79 | 1 |
| Company Overview | 79 | 4 |
| Hoffmann-La Roche Ltd. | 83 | 1 |
| Company Overview | 83 | 4 |
| Merck &Co., Inc | 87 | 1 |
| Company Overview | 87 | 9 |
| Eli Lilly and Company | 96 | 1 |
| Company Overview | 96 | 8 |
| Abbott Laboratories | 104 | 1 |
| Company Overview | 104 | 4 |
| Sanofi | 108 | 1 |
| Company Overview | 108 | 6 |
| Novo Nordisk | 114 | 1 |
| Company Overview | 114 | 3 |
| Amgen | 117 | 1 |
| Company Overview | 117 | 2 |
| Biogen | 119 | 1 |
| Company Overview | 119 | 2 |
| Therapeutic Proteins Market Strategic Consolidations | 121 | 16 |
| Therapeutic Proteins Market Mergers and Acquisitions | 121 | 1 |
| M&A Deals by Year | 121 | 1 |
| M&A Deals by Value | 122 | 1 |
| M&A Deals by Drug Class | 122 | 1 |
| M&A Deals by Geography | 123 | 1 |
| Major M&A Deals | 124 | 1 |
| Pfizer Completes Acquisition of Wyeth | 124 | 1 |
| Merck &Co Completes Merger with Schering-Plough | 124 | 1 |
| Takeda Acquires Millennium Pharmaceuticals | 125 | 1 |
| Eli Lilly Acquires ImClone Systems | 125 | 1 |
| Teva Pharmaceutical Industries Completes Acquisition of ratiopharm | 125 | 1 |
| Global Therapeutic Proteins Market Licensing Deals | 126 | 1 |
| Licensing Deals by Year | 126 | 1 |
| Licensing Deals by Value | 127 | 1 |
| Licensing Deals by Drug Class | 128 | 1 |
| Licensing Deals by Geography | 129 | 1 |
| Major Licensing Deals | 129 | 1 |
| Bristol-Myers Squibb Enters Into a Collaboration With ZymoGenetics | 129 | 1 |
| Amgen Enters Into Licensing Agreement With Kyowa Hakko Kirin | 130 | 1 |
| Lpath Enters Into Licensing Agreement With Pfizer | 130 | 1 |
| Micromet Enters Into Licensing Agreement With Sanofi-Aventis | 130 | 1 |
| Exelixis Enters Into Licensing Agreement With Bristol-Myers Squibb for XL475 | 131 | 1 |
| Global Therapeutic Proteins Market Co-Development Deals | 132 | 1 |
| Co-Development Deals by Year | 132 | 1 |
| Co-Development Deals by Value | 133 | 1 |
| Co-Development Deals by Drug Class | 133 | 1 |
| Co-Development Deals by Geography | 134 | 1 |
| Major Co-Development Deals | 134 | 1 |
| Eli Lilly Enters Into Co-Development Agreement with Boehringer Ingelheim | 135 | 1 |
| GlaxoSmithKline Enters Into Co-Development Agreement With Chroma Therapeutics | 135 | 1 |
| Wyeth Pharmaceuticals Enters Into Co-Development Agreement With Catalyst Biosciences | 135 | 1 |
| Galapagos Expands Co-Development Agreement With Merck &Co. | 136 | 1 |
| Galapagos Enters Into an Agreement With Merck | 136 | 1 |
| Global Therapeutic Proteins Market: Appendix | 137 | 6 |
| Market Definitions | 137 | 1 |
| Abbreviations | 137 | 1 |
| Research Methodology | 137 | 2 |
| Coverage | 137 | 1 |
| Secondary Research | 138 | 1 |
| Primary Research | 138 | 1 |
| Therapeutic Landscape | 139 | 2 |
| Epidemiology-based Forecasting | 139 | 1 |
| Market Size by Geography | 140 | 1 |
| Geographical Landscape | 141 | 1 |
| Pipeline Analysis | 141 | 1 |
| Competitive Landscape | 141 | 1 |
| Expert Panel Validation | 141 | 1 |
| Contact Us | 141 | 1 |
| Disclaimer | 141 | 1 |
| Sources | 142 | 1 |